Sirolimus Monotherapy as Maintenance Immunosuppression: Single-Center Experience in 50 Kidney Transplant Patients

Transplantation Proceedings

Volumn 39, Issue 7, 2007, Pages 2131-2134

  Arellano, E M ^a,b   Campistol, J M ^a   Oppenheimer, F ^a   Rovira, J ^a   Diekmann, F ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; ERYTHROPOIETIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; PREDNISONE; RAPAMYCIN;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; EPISTAXIS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GRAFT REJECTION; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY TRANSPLANTATION; LABORATORY TEST; LIVER FAILURE; MALE; MONOTHERAPY; MOUTH ULCER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEINURIA; RASH;

DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; REOPERATION; SIROLIMUS; TIME FACTORS;

EID: 34548672380     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.06.056     Document Type: Article

References (15)

1. Vajdic C.M., McDonald S.P., McCredie M.R., et al. Cancer incidence before and after Kidney transplantation. JAMA 296 (2006) 2823
2. Kiberd M., Panek R., and Kiberd B.A. New onset diabetes mellitus post-kidney transplantation. Clin Transplant 20 (2006) 634
3. Ojo A.O. Cardiovascular complications after renal transplantation and their prevention. Transplantation 82 (2006) 603
4. Franceschini N., Alpers C., Bennett W., et al. Cyclosporine arteriolopathy: effects of drug withdrawal. Am J Kidney Dis 32 (1998) 247
5. Webster A.C., Lee V.W.S., Chapman J.R., et al. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 81 (2006) 1234
6. Diekmann F., Gutiérrez-Dalmau A., Torregrosa J.V., et al. Sirolimus monotherapy: feasible immunosuppression for long-term follow-up of kidney transplantation-a pilot experience. Transplantation 80 (2005) 1344
7. Watson C., Firth J., Williams P.F., et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 5 (2005) 2496
8. Alexander J.W., Goodman H.R., Cardi M., et al. Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation. Transpl Int 19 (2006) 295
9. Lebbe C., Euvrard S., Barrouc B., et al. Sirolimus conversion for patients with posttransplant Kaposi's sarcoma. Am J Transplant 6 (2006) 2164
10. Gutierrez-Dalmau A., Sanchez-Fructuoso A., Sanz-Guajardo A., et al. Efficacy of conversion to sirolimus in posttransplantation Kaposi's sarcoma. Transplant Proc 37 (2005) 3836
11. Campistol J.M., Eris J., Oberbauer R., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17 (2006) 581
12. Sirolimus European Renal Transplant Study Group, Legendre C., Campistol J.M., Squifflet J.P., et al. Cardiovascular risk factors of Sirolimus compared with cyclosporine: early experience from two randomized trials in renal transplantation. Transplant Proc 35 3 suppl (2003) 151S
13. Castro C., Campistol J.M., Sancho D., et al. Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a P27 Kip1-independent pathway. Atherosclerosis 172 (2004) 31
14. Battaglia M., Stabilini A., and Roncarolo M.G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 105 (2005) 4743
15. Battaglia M., Stabilini A., and Roncarolo M.G. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 15 (2006) 8338